Orchestra BioMed Holdings (OBIO) Cash from Investing Activities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Investing Activities for 4 consecutive years, with -$17.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 371.94% to -$17.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.9 million through Dec 2025, down 305.83% year-over-year, with the annual reading at -$26.9 million for FY2025, 305.83% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$17.7 million at Orchestra BioMed Holdings, up from -$38.6 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $33.2 million in Q4 2023, with the low at -$63.4 million in Q4 2022.
  • Average Cash from Investing Activities over 4 years is -$4.2 million, with a median of $255000.0 recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 5879.91% in 2023, while the deepest fall reached 92514.89% in 2023.
  • Over 4 years, Cash from Investing Activities stood at -$63.4 million in 2022, then soared by 152.31% to $33.2 million in 2023, then crashed by 111.32% to -$3.8 million in 2024, then plummeted by 371.94% to -$17.7 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$17.7 million, -$38.6 million, and $16.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.